This page lists the cardiothoracic & vascular surgery hospitals in our directory offering Myocardial Bridge Treatment in Hyderabad, India, including KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills. Each listing links through to the hospital's full profile page.
Ask us about myocardial bridge treatment in Hyderabad, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 4 accredited hospitals for Cardiothoracic & Vascular Surgery in Hyderabad, India
Featured🇮🇳 KIMS Hospitals, Secunderabad
Ranks #1 in this list by listed rating (4.8/5 from 743 reviews).
🇮🇳 Yashoda Hospitals, Secunderabad
Ranks #2 in this list by listed rating (4.7/5 from 518 reviews).
🇮🇳 Apollo Hospital DRDO
Ranks #3 in this list by listed rating (4.5/5 from 82 reviews).
🇮🇳 Apollo Hospitals, Jubilee Hills
Ranks #4 in this list by listed rating (4.1/5 from 44 reviews).
How we selected these hospitals
A hospital appears on this page when Cardiothoracic & Vascular Surgery is among its listed specialties and it is located in Hyderabad, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Myocardial Bridge Treatment in Hyderabad, India?
Choosing the right hospital for myocardial bridge treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cardiothoracic & vascular surgery rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Myocardial Bridge Treatment
Myocardial bridge is a congenital coronary anomaly in which a segment of a major coronary artery — most commonly the left anterior descending (LAD) — tunnels beneath the myocardial muscle rather than running along the epicardial surface, causing systolic compression and, in symptomatic cases, significant ischemia, angina, arrhythmia, or even sudden cardiac death. Definitive management ranges from optimised pharmacotherapy with beta-blockers or non-dihydropyridine calcium channel blockers to advanced interventional or surgical relief — including unroofing myotomy and coronary artery bypass grafting (CABG) — with published series reporting symptom resolution or marked improvement in more than 85–92% of appropriately selected surgical candidates. GAF Healthcare connects international patients with JCI- and NABH-accredited cardiac centres in India and JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi, offering world-class diagnostic work-ups, subspecialist cardiothoracic surgeons, and end-to-end concierge logistics at a fraction of Western costs. Hospital Stay: 3–7 days (medical management) to 7–12 days (surgical unroofing or CABG) • Total Stay in Country (Fit-to-Fly): 2–3 weeks for pharmacological optimisation; 5–8 weeks post open-heart surgery or robotic unroofing before safe long-haul flight • Success Rate: 85–92% symptomatic relief with surgery; >90% angina-free at 1 year in high-volume centre series
Clinical Overview
A myocardial bridge occurs when a coronary artery segment — most frequently the mid-LAD (reported in 25–80% of autopsy series, symptomatic in 0.5–2.5% of angiographic populations) — courses intramurally through the ventricular myocardium for a distance ranging from a few millimetres to several centimetres. During systole, myocardial contraction compresses the tunnelled segment, generating a characteristic 'milking effect' on coronary angiography; diastolic flow, which normally accounts for the majority of coronary perfusion, is also impaired because residual post-systolic compression and elevated diastolic tone shorten the effective filling window. The haemodynamic consequence is a reduction in coronary flow reserve (CFR) — measurable by fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) during pharmacological provocation — leading to demand ischaemia, microvascular dysfunction, and, in severe cases, transient endothelial injury that paradoxically accelerates atherosclerosis proximal to the bridge. Clinically, patients present on a broad spectrum: incidental finding on CT coronary angiography (CTCA) at one end, to exertional angina, exercise-induced ST depression, ventricular tachyarrhythmia, Takotsubo-like syndrome, or syncope at the other. Risk stratification is guided by invasive haemodynamic assessment — FFR ≤ 0.80 or diastolic FFR ≤ 0.76 under adenosine provocation, intracoronary acetylcholine testing for vasospasm, and intravascular ultrasound (IVUS) to characterise bridge length and depth — supplemented by non-invasive stress perfusion imaging (cardiac MRI with adenosine stress, myocardial perfusion SPECT, or PET-CT) to quantify ischaemic burden. The global standard of care, as reflected in ESC and ACC/AHA guidance, begins with optimised medical therapy: beta-1 selective blockers (metoprolol succinate, bisoprolol) to reduce heart rate and systolic compression duration, or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) when beta-blockers are contraindicated. Nitrates and intra-coronary stenting are contraindicated or discouraged — nitrates worsen systolic compression by increasing contractility reflexively, and stent placement carries prohibitively high rates of fracture and restenosis within the bridge segment. Patients failing medical therapy, demonstrating significant FFR-proven ischaemia, or presenting with malignant arrhythmia are referred for definitive surgical relief.
Who is a Candidate?
• ELIGIBLE PATIENTS: • Symptomatic patients (angina CCS Class II–IV, dyspnoea, palpitations, syncope) despite ≥3 months of optimised beta-blocker or non-dihydropyridine CCB therapy • Objective haemodynamic significance confirmed by FFR ≤ 0.80 or diastolic FFR ≤ 0.76 under adenosine, or iFR ≤ 0.89 • Documented inducible ischaemia on non-invasive imaging: stress cardiac MRI, adenosine stress SPECT/PET-CT showing ≥10% ischaemic myocardium, or stress ECHO with wall-motion abnormalities in the LAD territory • Bridge length ≥ 20 mm or depth ≥ 5 mm on IVUS/CTCA, predictive of surgical feasibility of unroofing myotomy • Patients with exercise-induced ventricular tachycardia or documented aborted sudden cardiac death attributable to bridge-related ischaemia • Young patients (typically <50 years) without significant proximal atherosclerosis, where unroofing is preferred over CABG to preserve native coronary anatomy • REQUIRED DIAGNOSTIC WORK-UP BEFORE TREATMENT: • 64-slice or higher Dual-Source CTCA with cardiac gating — to measure bridge length, depth, and angulation, and assess proximal atherosclerosis • Invasive coronary angiography with pharmacological provocation (ergometrine or acetylcholine) to demonstrate milking effect and exclude significant fixed obstructive disease • Resting and adenosine-stress FFR / iFR measurement across the bridge segment • IVUS or Optical Coherence Tomography (OCT) to assess plaque, vessel remodelling, and peri-bridge anatomy • Adenosine stress cardiac MRI (preferred) OR Rb-82 / N-13 ammonia PET-CT for absolute myocardial blood flow and CFR quantification • 12-lead ECG, 24–72-hour Holter monitor (to exclude ventricular arrhythmia burden) • Transthoracic echocardiogram (ECHO) — LV function, regional wall motion, haemodynamic baseline • Full pre-operative labs: CBC, BMP, coagulation panel, HbA1c, thyroid panel, lipid profile • CONTRAINDICATIONS / RELATIVE EXCLUSIONS: • Asymptomatic incidental bridge with normal CFR and negative stress imaging (medical observation only) • EF < 30% with diffuse LV dysfunction not attributable to bridge ischaemia • Significant co-morbidities precluding surgery (STS/EuroSCORE II > 10% without multidisciplinary heart team consensus) • Prior CABG with patent grafts to the LAD territory (re-operation risk outweighs benefit in most cases) • Coagulopathy or severe thrombocytopaenia uncorrectable pre-operatively
Treatment Options & Approaches
TIER 1 — OPTIMISED PHARMACOLOGICAL MANAGEMENT (First-Line): Beta-1 selective adrenergic blockade is the pharmacological cornerstone. Bisoprolol (2.5–10 mg/day) or metoprolol succinate (25–200 mg/day) reduce resting and peak-exercise heart rate, prolonging diastole and thereby increasing the effective coronary perfusion window. Target resting HR 55–65 bpm. For patients with beta-blocker intolerance or predominantly vasospastic phenotype, non-dihydropyridine CCBs — verapamil (240–480 mg/day SR) or diltiazem (120–360 mg/day SR) — are used. Ivabradine (5–7.5 mg BID) can be added as an adjunct for rate control without negative inotropy, particularly valuable in patients with borderline LV function. Antiplatelet therapy (aspirin 75–100 mg/day) is considered where proximal plaque is detected. Sublingual and long-acting nitrates are specifically contraindicated. TIER 2 — SURGICAL UNROOFING MYOTOMY (Definitive Surgical Standard): Surgical unroofing (supracoronary myotomy) is the treatment of choice for symptomatic patients refractory to medical therapy, with bridge lengths amenable to dissection. The procedure involves cardiopulmonary bypass (CPB) with cardioplegic arrest; the myocardial fibres overlying the tunnelled coronary segment are sharply incised and excised, releasing the artery to an epicardial position. Operating time for the unroofing component is typically 15–45 minutes once CPB is established. Published case series (Iversen et al., Mohlenkamp, Alegria) report 88–95% freedom from angina at 2-year follow-up, normalisation of FFR post-procedure, and regression of stress-perfusion defects. Contemporary centres are now performing unroofing via minimally invasive right anterolateral mini-thoracotomy or robotic-assisted thoracoscopic approach (da Vinci Surgical System), reducing ICU stay to 24–48 hours and total hospital stay to 5–7 days versus 8–12 days for conventional sternotomy. TIER 3 — CORONARY ARTERY BYPASS GRAFTING (CABG) — Selected Cases: CABG is preferred when: (a) significant proximal atherosclerosis co-exists and unroofing would not address the obstructive disease, (b) bridge anatomy precludes safe surgical unroofing (deep intramyocardial course, short segment with unfavourable angulation), or (c) prior unroofing has failed. Off-pump CABG (OPCAB) using the left internal mammary artery (LIMA) to the distal LAD — with or without sequential grafts — is favoured to avoid CPB-related morbidity. In patients with isolated bridge and no atherosclerosis, CABG provides competitive myocardial blood flow but creates a 'competitive flow' scenario that may reduce graft patency long-term; this is weighed carefully by the heart team. Total arterial revascularisation strategies using bilateral IMA or radial artery grafts are employed in younger patients. TIER 4 — PERCUTANEOUS CORONARY INTERVENTION (PCI) — Exceptional and Discouraged: Percutaneous stenting of the bridged segment is generally contraindicated due to high stent fracture rates (reported 20–30% at 2 years), neo-atherosclerosis, ISR, and risk of perforation. Bare metal or drug-eluting stents placed within the bridge are associated with significant long-term failure. PCI is only considered in extreme high-surgical-risk cases as a bridge-to-decision strategy, with full patient counselling regarding inferior durability. TIER 5 — ELECTROPHYSIOLOGY INTERVENTION (Adjunctive): Patients presenting with ventricular tachycardia or fibrillation attributable to bridge ischaemia may require ICD implantation concurrent with or following surgical unroofing, pending arrhythmia substrate elimination confirmed by post-operative electrophysiological study.
Recovery
PHASE 1 — REMOTE PRE-CONSULTATION (Weeks 1–2, From Home Country): • Patient submits medical records, coronary angiogram reports, CTCA images, and stress test results to GAF Healthcare's dedicated cardiology coordination team via secure portal • GAF assigns a subspecialist interventional cardiologist or cardiothoracic surgeon for a telemedicine second opinion within 48–72 hours • GAF provides a written treatment plan, itemised cost estimate, and destination recommendation (India or UAE) based on case complexity, urgency, and patient preference • e-Medical visa application process initiated for India (typically approved in 3–5 business days); UAE visit/medical visa facilitated via sponsor letter PHASE 2 — ARRIVAL AND DIAGNOSTIC WORK-UP (Days 1–4 In-Country): • Day 1: Airport pickup by dedicated GAF medical concierge; hotel/hospital accommodation check-in; orientation briefing with assigned patient coordinator • Days 2–3: Comprehensive cardiac diagnostic protocol — fasting bloodwork, 12-lead ECG, transthoracic ECHO, adenosine-stress cardiac MRI or PET-CT, Holter monitoring • Day 3–4: Invasive coronary angiography with FFR/iFR assessment and IVUS under conscious sedation (day-case or overnight admission); CTCA review by interventional cardiologist and cardiothoracic surgeon jointly • Heart Team Conference: Cardiologist, cardiothoracic surgeon, electrophysiologist, and anaesthesiologist meet to confirm treatment plan, obtain informed consent, and schedule procedure PHASE 3 — PROCEDURE DAY (Day 5–6): • Medical management patients: Pharmacological optimisation initiated; monitored 24–48 hours; no procedure required • Surgical unroofing (conventional or robotic): General anaesthesia with TEE monitoring; CPB established (or robotic port placement); unroofing myotomy performed; haemostasis confirmed; repeat intraoperative FFR/IVUS to confirm anatomical success; chest closure; transfer to cardiac ICU • CABG patients: OPCAB or on-pump CABG with LIMA-to-LAD anastomosis; transit-time flow measurement (TTFM) to verify graft patency before chest closure; ICU transfer PHASE 4 — ICU AND STEP-DOWN RECOVERY (Days 1–5 Post-Procedure): • ICU: Typically 24–48 hours (robotic/minimally invasive) to 48–72 hours (sternotomy); haemodynamic monitoring, early extubation protocol, chest drain management • Days 2–4: Transfer to monitored step-down ward; early ambulation protocol initiated (sitting up Day 1, standing Day 2, corridor walking Day 3); respiratory physiotherapy; wound care • Day 4–5: Removal of chest drains; repeat ECHO to assess LV function and exclude pericardial effusion; repeat ECG • Beta-blocker and antiplatelet therapy commenced or continued; statin therapy initiated if atherosclerosis present PHASE 5 — HOSPITAL DISCHARGE AND IN-COUNTRY RECOVERY (Days 7–14 Post-Procedure): • Discharge criteria: Afebrile, haemodynamically stable, ambulatory, wound healing, no arrhythmia burden on telemetry • GAF-arranged recovery accommodation (serviced apartment or hospital-affiliated guest house) for patient and attendant • Outpatient cardiology review at Day 10–12: wound inspection, Holter monitoring, repeat ECHO, exercise tolerance assessment • Cardiac rehabilitation sessions (supervised, 3×/week) initiated at Day 10 for surgical patients • Stress perfusion imaging (nuclear or MRI) recommended at 4–6 weeks post-discharge to confirm resolution of ischaemia PHASE 6 — FIT-TO-FLY CLEARANCE AND DEPARTURE (Weeks 5–8 Post-Procedure): • Medical management patients: Fit to fly in 2–3 weeks after pharmacological optimisation and stable Holter • Post-surgical patients: Conventional sternotomy — fit to fly typically at 6–8 weeks; minimally invasive/robotic — 4–6 weeks • GAF provides a formal fit-to-fly medical letter, summary discharge report, and digital imaging archive for the patient's home cardiologist • Remote 3-month and 12-month virtual cardiology follow-up arranged through GAF's telehealth platform
Risks to be aware of
As with all cardiac interventions, myocardial bridge treatment carries procedure-specific risks that patients must understand in order to make informed consent decisions. For surgical unroofing myotomy, the principal risks include: inadvertent coronary arteriotomy or laceration during dissection of the tunnelled segment (requiring intraoperative repair or conversion to CABG, reported in 1–3% of series); post-operative pericardial effusion or late constrictive pericarditis (2–5%); wound infection or sternal dehiscence (1–2% with standard sternotomy); transient atrial fibrillation (20–30% in the first 48–72 hours post-bypass, usually self-limiting or pharmacologically managed); and a procedural mortality risk of 0.5–1.5% in elective, non-emergent cases at high-volume centres with STS-predicted risk < 2%. For CABG, additional risks include graft occlusion (competitive flow phenomenon specific to bridged LAD, particularly in segments with preserved antegrade native flow), vein graft failure at 10 years (~30–40%), and neurological complications related to CPB (stroke risk <1% in elective cases at experienced centres). Robotic and minimally invasive approaches reduce chest wall morbidity, ICU stay, and blood loss but carry a learning-curve risk and potential for conversion to open sternotomy. Pharmacological therapy risks include bradycardia, hypotension, and bronchospasm with beta-blockers; constipation, AV nodal suppression, and negative inotropy with non-dihydropyridine CCBs. Patients must disclose all concurrent medications, particularly phosphodiesterase-5 inhibitors (absolutely contraindicated with nitrates if accidentally prescribed). Long-term, untreated haemodynamically significant bridges carry a risk of accelerated proximal atherosclerosis and, in a minority, malignant ventricular arrhythmia — emphasising that watchful waiting in symptomatic, FFR-positive cases carries its own risk profile that often exceeds the procedural risk at expert centres.
Why GAF Healthcare
GAF Healthcare provides a fully integrated medical travel programme that addresses every logistical dimension of the patient journey, from the moment a treatment plan is confirmed to the day of departure home. VISA AND DOCUMENTATION — INDIA: GAF facilitates the e-Medical Visa (e-MV) application for India, which is available to nationals of over 160 countries. The e-MV permits triple entry over a 60-day period specifically for medical treatment purposes. GAF's documentation team prepares the hospital invitation letter, treatment plan certificate, and proof of admission required by the Indian immigration authority (FRRO). Visa fees and processing take approximately 3–5 business days online. A companion/attendant e-Medical Visa (e-MCV) is simultaneously arranged for one accompanying family member. VISA AND DOCUMENTATION — UAE (DUBAI / ABU DHABI): Nationals of GCC countries, most EU/UK, and many ASEAN nations enjoy visa-free or visa-on-arrival access to the UAE for up to 30–90 days. Patients from countries requiring advance visas receive a sponsor letter from the GAF-affiliated UAE hospital, enabling a medical treatment entry visa. Patients under Dubai Health Authority (DHA) or Abu Dhabi Health Services (SEHA/HAAD) regulated facilities may also access patient rights protections under UAE federal health law. AIRPORT TRANSFERS AND GROUND LOGISTICS: A dedicated GAF patient coordinator meets arriving patients at the airport with personalised signage, arranges air-conditioned private transport to the hospital or recovery accommodation, and accompanies patients to all initial registration and diagnostic appointments. For post-surgical patients, wheelchair-accessible vehicles and medical escort (nurse or paramedic) are available upon request. ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF arranges accommodation in hospital-affiliated guest houses, serviced apartments, or partner hotels located within 5–15 minutes of the treating hospital. Attendant accommodation (single room with kitchenette) is included in most GAF package agreements. Meals, laundry, and housekeeping are available as add-ons. For patients requiring extended post-operative stays (cardiac rehabilitation phase), long-stay apartment contracts are negotiated at preferred rates. MEDICAL TRANSLATION AND INTERPRETATION: GAF provides professional medical interpreters in Arabic, Russian, Bangla, French, Swahili, and other major patient-origin languages at no additional charge for consultations, consent discussions, and discharge briefings. All written medical summaries, discharge reports, and follow-up care plans are translated into the patient's preferred language. COMMUNICATION AND CONTINUITY OF CARE: Each patient is assigned a named GAF case manager who serves as the single point of contact throughout the journey — reachable via WhatsApp, phone, and email 7 days a week. Post-discharge, the GAF telehealth team facilitates virtual cardiology follow-up appointments at 1 month, 3 months, and 12 months, and transmits full imaging and clinical records to the patient's home country cardiologist in DICOM and PDF formats.
Common questions about Myocardial Bridge Treatment
What is the cost of Myocardial Bridge Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Myocardial Bridge Treatment?
What is the success rate of Myocardial Bridge Treatment?
How GAF Healthcare Assists in Choosing the Best Hospital for Myocardial Bridge Treatment in Hyderabad, India
Discover the Top Hospitals for Myocardial Bridge Treatment in Hyderabad, India
This page lists 4 accredited cardiothoracic & vascular surgery hospitals in Hyderabad, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about myocardial bridge treatment in Hyderabad, India
How many cardiothoracic & vascular surgery hospitals are listed in Hyderabad, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there cardiothoracic & vascular surgery hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for myocardial bridge treatment in Hyderabad, India.
Contact us to report an inaccuracy on this page.